Immunological Response After Shrimp Oral Immunotherapy Treatment

Status Active, not recruiting

Clinical Trial Summary

Oral immunotherapy is effective in desensitized food allergy. Shrimp allergy is increasing in Thailand. So the purpose of our study is to determine level of specific immunoglobulin E antibodies to shrimp, Immunoglobulin G4 and immunoblot analysis in shrimp allergy patients after shrimp oral immunotherapy.

Clinical Trial Description

All subject in this study were sensitized to shrimp. All patient was clinically evaluated, with focus on shrimp allergy by medical history, medical examination and gold standard oral food challenge test. Compare oral immunotherapy to shrimp and shrimp avoidance. Blood sample was taken for baseline determination of immunoglobulin E antibodies to shrimp. The primary outcome was the specific immunoglobulin E antibodies to shrimp,Immunoglobulin G4 and immunoblot analysis in case that oral immunotherapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04552522
Study type	Interventional
Source	Mahidol University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	August 28, 2020
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05848011` - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer	Phase 2
Recruiting	`NCT05161572` - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer	Phase 2
Recruiting	`NCT06165900` - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC	Phase 2
Recruiting	`NCT06120127` - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence	Phase 2
Recruiting	`NCT06262581` - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery	Phase 2
Recruiting	`NCT05176002` - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.	Phase 1/Phase 2
Not yet recruiting	`NCT05909137` - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting	`NCT04500990` - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting	`NCT04372732` - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed	`NCT02692976` - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients	Phase 2
Completed	`NCT03763630` - MAPS & ITEC Cohorts: 6-8 Years Follow-up	Phase 2
Not yet recruiting	`NCT06012318` - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting	`NCT05479240` - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer	Phase 2
Recruiting	`NCT05515796` - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors	Phase 2
Recruiting	`NCT04711330` - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting	`NCT03701607` - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting	`NCT03683407` - Effect of Chemotherapy on TMB in NSCLC
Completed	`NCT03357861` - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Recruiting	`NCT05223088` - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer	Phase 2
Completed	`NCT05657262` - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas	N/A